Skip to main content
Premium Trial:

Request an Annual Quote

Atugen Reaches Nine Milestones in Schering Target Validation Deal

NEW YORK, May 9 (GenomeWeb News) - Atugen said today that it reached nine milestones under its target validation research deal with German drug maker Schering and its US subsidiary, Berlex Biosciences.

 

According to Atugen, it received milestone payments on nine of Scheing's cancer drug targets that were validated by Atugen using its proprietary gene-silencing technologies since the companies began working together in 2002.

 

Financial terms of the arrangement, which an Atugen spokeswoman said has now been completed, are undisclosed.

 

 

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.